JG
ALXN

Jefferies Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Jefferies Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-57,500
Closed -$10.6M – 2217
2021
Q2 		$10.6M Buy
57,500
+44,184
+332% +$7.58M 0.07% 263
2021
Q1 		$2.04M Sell
13,316
-72,472
-84% -$11.2M 0.02% 675
2020
Q4 		$13.4M Buy
85,788
+79,594
+1,285% +$10.2M 0.11% 162
2020
Q3 		$709K Buy
6,194
+4,983
+411% +$538K 0.01% 903
2020
Q2 		$136K Sell
1,211
-11,309
-90% -$1.2M ﹤0.01% 1096
2020
Q1 		$1.09M Sell
12,520
-44,395
-78% -$4.36M 0.01% 969
2019
Q4 		$6.16M Buy
56,915
+16,274
+40% +$1.74M 0.05% 427
2019
Q3 		$3.98M Buy
40,641
+31,686
+354% +$3.57M 0.03% 652
2019
Q2 		$1.17M Buy
8,955
+5,909
+194% +$762K 0.01% 1206
2019
Q1 		$412K Sell
3,046
-18,298
-86% -$2.28M ﹤0.01% 1677
2018
Q4 		$2.08M Buy
21,344
+19,737
+1,228% +$2.33M 0.02% 801
2018
Q3 		$223K Sell
1,607
-71,762
-98% -$9M ﹤0.01% 2056
2018
Q2 		$9.11M Buy
73,369
+65,383
+819% +$7.64M 0.05% 294
2018
Q1 		$890K Buy
+7,986
New +$955K ﹤0.01% 1252
2017
Q4 		– Sell
-50,521
Closed -$7.09M – 2923
2017
Q3 		$7.09M Buy
50,521
+29,527
+141% +$4.01M 0.05% 401
2017
Q2 		$2.55M Sell
20,994
-36,439
-63% -$4.24M 0.02% 839
2017
Q1 		$6.96M Buy
+57,433
New +$7.4M 0.05% 375
2016
Q3 		– Sell
-34,441
Closed -$4.02M – 2542
2016
Q2 		$4.02M Buy
34,441
+29,797
+642% +$4.23M 0.02% 573
2016
Q1 		$647K Sell
4,644
-17,631
-79% -$2.59M ﹤0.01% 1324
2015
Q4 		$4.25M Sell
22,275
-16,549
-43% -$2.89M 0.02% 544
2015
Q3 		$6.07M Buy
38,824
+6,787
+21% +$1.24M 0.03% 413
2015
Q2 		$5.79M Buy
+32,037
New +$5.53M 0.03% 462
2014
Q4 		– Sell
-5,116
Closed -$848K – 2458
2014
Q3 		$848K Sell
5,116
-5,227
-51% -$858K 0.01% 1081
2014
Q2 		$1.62M Buy
+10,343
New +$1.63M 0.01% 714
2014
Q1 		– Sell
-771
Closed -$102K – 2473
2013
Q4 		$102K Sell
771
-2,438
-76% -$293K ﹤0.01% 1698
2013
Q3 		$373K Buy
3,209
+2,959
+1,184% +$325K ﹤0.01% 1335
2013
Q2 		$23K Buy
+250
New +$24.1K ﹤0.01% 1729

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Jefferies Group's ALXN Position: Q3 2021 in Review

Jefferies Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 57,500 shares — an estimated $10.6M sold.

Jefferies Group first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $13.4M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jefferies Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jefferies Group sold 57,500 Alexion Pharmaceuticals shares in Q3 2021, an estimated $10.6M.
  • Jefferies Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Jefferies Group's Alexion Pharmaceuticals position peaked at $13.4M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.